The Group's principal activity is to create new standards of care in therapeutic areas with high unmet medical needs. It discovers, develops, manufactures and commercializes innovative therapies. Its products include: TYSABRI(R) the most recently approved treatment for relapsing forms of MS, AVONEX(R) with quality prescribed therapy for relapsing forms of MS worldwide and RITUXAN(R) most prescribed therapy for non-Hodgkin's lymphoma and rheumatoid arthritis. It operates in Massachusetts, Switzerland, US, Canada, Australia, Japan and Europe.
Alacra Alerts:
Receive alerts on the latest reports on Biogen Idec Inc
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
